Literature DB >> 26070847

Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?

Ville Sallinen1, Caj Haglund2, Hanna Seppänen2.   

Abstract

BACKGROUND: Nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) are rare tumors with highly variable outcome. Current guidelines recommend surveillance for small tumors (≤ 2 cm), but a scientific basis for such recommendation is scarce.
METHODS: Patients who underwent surgery for NF-PNET during 2001-2013 were identified from a prospectively maintained database and reviewed retrospectively.
RESULTS: Fifty-eight patients that had undergone an operative procedure for NF-PNET were identified. Forty-one patients (71%) were symptomatic. Median size of the tumor was 2.5 cm (range 0.9-12.0 cm). WHO 2010 grade was predictive of both overall- and disease-free survival (P < .001), whereas size alone was not. Twenty-four patients had a small NF-PNET (≤ 2 cm), of whom 16 were symptomatic and 8 asymptomatic. Seven patients with small symptomatic NF-PNETs showed signs of malignant behavior: 4 had lymph node metastases, 1 had liver metastases before surgery, 3 developed liver metastases, and 3 died of the disease. All 7 patients had either bile duct or pancreatic duct obstruction or both on preoperative imaging. On the contrary, patients with small asymptomatic NF-PNETs did not develop distant metastases nor died of disease.
CONCLUSION: The 2010 grading system from the World Health Organization can be used to predict survival. Symptomatic small NF-PNETs that caused bile and/or pancreatic duct obstruction had poor outcome. In contrast, asymptomatic small NF-PNETs seem to have benign course, and are candidates for surveillance.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26070847     DOI: 10.1016/j.surg.2015.04.035

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  16 in total

1.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

Review 2.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 3.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

4.  Qualitative imaging features of pancreatic neuroendocrine neoplasms predict histopathologic characteristics including tumor grade and patient outcome.

Authors:  Motoyo Yano; Anup S Shetty; Greg A Williams; Samantha Lancia; Nikolaos A Trikalinos; Chet W Hammill; William G Hawkins; Amber Salter; Deyali Chatterjee
Journal:  Abdom Radiol (NY)       Date:  2022-02-15

Review 5.  Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.

Authors:  Samuel J Galgano; Ajaykumar C Morani; Dheeraj R Gopireddy; Kedar Sharbidre; David D B Bates; Ajit H Goenka; Hina Arif-Tiwari; Malak Itani; Amir Iravani; Sanaz Javadi; Silvana Faria; Chandana Lall; Emily Bergsland; Sadhna Verma; Isaac R Francis; Daniel M Halperin; Deyali Chatterjee; Priya Bhosale; Motoyo Yano
Journal:  Abdom Radiol (NY)       Date:  2022-03-04

6.  Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.

Authors:  V Andreasi; C Ricci; R Casadei; M Falconi; S Partelli; G Guarneri; C Ingaldi; F Muffatti; S Crippa
Journal:  J Endocrinol Invest       Date:  2021-11-13       Impact factor: 4.256

7.  Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database.

Authors:  Abuduhaibaier Sadula; Gang Li; Dianrong Xiu; Chen Ye; Siqian Ren; Xin Guo; Chunhui Yuan
Journal:  Comput Math Methods Med       Date:  2022-05-12       Impact factor: 2.809

Review 8.  Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.

Authors:  Vladimir Neychev; Electron Kebebew
Journal:  Int J Surg Oncol       Date:  2017-05-16

9.  Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines.

Authors:  Frederic Triponez; Samira M Sadowski; François Pattou; Catherine Cardot-Bauters; Eric Mirallié; Maëlle Le Bras; Frédéric Sebag; Patricia Niccoli; Sophie Deguelte; Guillaume Cadiot; Gilles Poncet; Jean-Christophe Lifante; Françoise Borson-Chazot; Philippe Chaffanjon; Olivier Chabre; Fabrice Menegaux; Eric Baudin; Philippe Ruszniewski; Hélène Du Boullay; Pierre Goudet
Journal:  Ann Surg       Date:  2018-07       Impact factor: 12.969

10.  Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours.

Authors:  Logan Mills; Panagiotis Drymousis; Yogesh Vashist; Christoph Burdelski; Andreas Prachalias; Parthi Srinivasan; Krishna Menon; Corina Cotoi; Saboor Khan; Judith Cave; Thomas Armstrong; Martin O Weickert; Jakob Izbicki; Joerg Schrader; Andreja Frilling; John K Ramage; Raj Srirajaskanthan
Journal:  Endocr Connect       Date:  2017-11       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.